VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Wide Moat Stocks Home My Collections

Stock Comparison

Gilead Sciences, Inc. vs Martin Marietta Materials, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Gilead Sciences, Inc.

GILD · NASDAQ Global Select Market

Market cap (USD)$150.9B

Gross margin (TTM)78.7%

Operating margin (TTM)36.1%

Net margin (TTM)27.9%

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUS

Data as of2025-12-30

Moat score

74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.

View GILD analysis

Martin Marietta Materials, Inc.

MLM · NYSE

Market cap (USD)$37.9B

Gross margin (TTM)—

Operating margin (TTM)—

Net margin (TTM)—

SectorMaterials

IndustryConstruction Materials

CountryUS

Data as of2026-01-01

Moat score

78/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Martin Marietta Materials, Inc.'s moat claims, evidence, and risks.

View MLM analysis

Comparison highlights

Moat score gap: Martin Marietta Materials, Inc. leads (78 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Martin Marietta Materials, Inc. has 3 segments (52.4% in East Group).
Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Martin Marietta Materials, Inc. has 4 across 2.

Primary market context

Gilead Sciences, Inc.

HIV

Market

HIV treatment and prevention medicines (antiretroviral therapy and PrEP)

Geography

Global (U.S. and Europe are major markets)

Customer

Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies

Role

Drug developer and marketing authorization holder

Revenue share

68.5%

Martin Marietta Materials, Inc.

East Group

Market

Construction aggregates and asphalt products (crushed stone, sand & gravel; asphalt) in local/regional markets

Geography

United States (East/Southeast and adjacent regions)

Customer

Infrastructure agencies, construction contractors, and downstream materials producers (asphalt/ready-mix)

Role

Quarry/mining operator and building materials producer/distributor

Revenue share

52.4%

Side-by-side metrics

Gilead Sciences, Inc.

Martin Marietta Materials, Inc.

Ticker / Exchange

GILD - NASDAQ Global Select Market

MLM - NYSE

Market cap (USD)

$150.9B

$37.9B

Gross margin (TTM)

78.7%

n/a

Operating margin (TTM)

36.1%

n/a

Net margin (TTM)

27.9%

n/a

Sector

Healthcare

Materials

Industry

Drug Manufacturers - General

Construction Materials

HQ country

Primary segment

HIV

East Group

Market structure

Oligopoly

Market share

50%-60% (reported)

n/a

HHI estimate

n/a

Pricing power

Moderate

Strong

Moat score

74 / 100

78 / 100

Moat domains

Demand, Legal, Supply

Supply, Financial

Last update

2025-12-30

2026-01-01

Moat coverage

Shared moat types

Capex Knowhow Scale

Gilead Sciences, Inc. strengths

Habit DefaultSwitching Costs GeneralIP Choke PointService Field NetworkCompliance AdvantageRegulated Standards PipeBrand Trust

Martin Marietta Materials, Inc. strengths

Physical Network DensityGeographic NaturalBenchmark Pricing Power

Segment mix

Gilead Sciences, Inc. segments

Full profile >

HIV

Oligopoly

68.5%

Oncology (Cell Therapy + Trodelvy)

Oligopoly

11.5%

Liver Disease

Oligopoly

10.6%

Veklury (Remdesivir)

Competitive

6.3%

Other Products

Competitive

3.1%

Martin Marietta Materials, Inc. segments

Full profile >

East Group

Oligopoly

52.4%

West Group

Oligopoly

40.9%

Specialties (formerly Magnesia Specialties)

Oligopoly

6.7%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.